… erlotinib and gefitinib in NSCLC patients harboring EGFR mutations. In this retrospective
study, … use of AS with EGFR-TKIs—erlotinib and gefitinib—on the efficacy and toxicity in clinical …

Background This study aimed to evaluate the efficacy, side-effects and resistance mechanisms
of first-line afatinib in a real-world setting. Methods This is a multicenter observational …

… According to these results: GEFITINIB, ERLOTINIB and more recently AFATINIB obtained
their registration for the treatment of patients with advanced NSCLC harboring an activating …

… EGFR-TKI combination is 250 mg gefitinib once a day, 150 mg erlotinib once a day, 125 mg
… A retrospective multicenter study by Bi N et al 9 showed that first-line TKI combined with RT …

… of the EGFR inhibitors gefitinib and erlotinib in the … research investigators on clinical trials
of gefitinib or erlotinib, served as consultants or on advisory boards for gefitinib and erlotinib, …

… Retrospective studies suggest that continuous use of EGFR-TKI beyond progressive disease
(PD) may benefit some pts. Objective: The purpose of our retrospective multicentric study is …

… to erlotinib and gefitinib. We undertook this study to explore the relationship between
EGFR mutation type and clinical variables, including treatment with gefitinib and erlotinib. …

… To investigate current clinical management beyond PD with gefitinib, multicenter survey was
… a retrospective study to assess the survival benefit of continued gefitinib treatment in these …

… retrospective analysis are slightly better for erlotinib (29.3 months) and similar for gefitinib
(27.3 months) compared to phase III studies. … treated with gefitinib or erlotinib assessed by us is …

… of a real-world, retrospective, global, and multi-center study (UpSwinG). The study used pre-…
consecutive patients treated with EGFR TKIs (erlotinib, gefitinib, afatinib, or osimertinib) and …